NEW YORK, March 06, 2024 (GLOBE NEWSWIRE) — Psyence Biomedical Ltd (NASDAQ:PBM) (“Psyence Biomed” or the “Company”) is pleased to announce that its wholly-owned subsidiary, Psyence Australia (Pty) Ltd (“Psyence Australia”), has received full approval from the Australian Health Research Ethics Committee (HREC) to initiate its planned Phase IIb study in Melbourne, Australia. The study will examine the use of nature-derived psilocybin as a treatment for Adjustment Disorder due to a recent cancer diagnosis in the palliative care context. Worldwide, an estimated 56.8 million people require palliative care annually, with a substantial number of these patients exhibiting a high burden of psychosocial distress after diagnosis.